



BENEFITS OF OLIGOPIN®



Oligopin® is a French maritime pine tree bark extract, cultivated from the largest forest in southern France. It has been clinically proven to support cardiovascular, vein, skin, male fertility and muscle health.

Dosage: 25-360mg once a day

INGREDIENT

French maritime pine tree (*Pinus pinaster*) extract containing oligomeric procyanidins standardised to **65%**.

Characteristics of Pine Bark

Pinus pinaster is rich in bioflavonoids and oligomeric procyanidins, nutrient members of the proanthocyanidin group of flavonoids. Multiple studies across human and animal models show that proanthocyanidins have significant health benefits for the cardiovascular system.

Oligomeric procyanidins are potent in antioxidant and anti-inflammatory properties and widely recognised for their health benefits across nutrition and medicine.

Clinical research into oligomeric proanthocyanidin across Europe has continuously proved its effectiveness in supporting a range of health categories.

1 Rauf, A., et al. (2019). Proanthocyanidins: A comprehensive review. https://doi.org/10.1016/j.biopha.2019.108999.


2 John F. Hammerstone, Sheryl A. Lazarus, Harold H. Schmitz, Procyanidin Content and Variation in Some Commonly Consumed Foods, *The Journal of Nutrition*, Volume 130, Issue 8, August 2000, Pages 2086S–2092S, https://doi.org/10.1093/jn/130.8.2086S.

3 Valls, R., et al. (2016) Effects pf low molecular weight procyanidin rich extract from french maritime pine bark on cardiovascular disease risk factors in stage-1 hypertensive subjects: Randomized, double-blind, crossover, placebo-controlled intervention trial. *Phytomedicine*. https://doi.org/10.1016/j.phymed.2016.08.007

4 Dridi, W. & Bordenave, N. (2020). Pine Bark Phenolic Extracts, Current Uses, and Potential Food Applications: A Review. *Current Pharmaceutical Design*. 26:1-14. doi: 10.2174/1381612826666200212113903

Cardiovascular health

A placebo-controlled, randomised, crossover 5-week study had stage-1 hypertensive subjects take 75mg of Oligopin® twice daily or a placebo. After 5 weeks, the following results were recorded:



Immunity

Glutathione is an essential component for the immune system, being the main antioxidant present in living organisms. A study has shown that supplementing with Oligopin® can increase glutathione production in our cells.

Skin Health

Studies suggest that pine bark extract may help improve skin elasticity and hydration, and reduce symptoms of aged skin such as wrinkles, hyperpigmentation and swelling.

The high antioxidant levels in pine bark extract help promote blood flow to the skin which protects it from UV damage and environmental stress, thereby reducing skin pigmentation and scar tissue.

To assist with skin health and beauty, pine bark extract can be applied topically over problem areas or taken as a supplement.

Lipa Pharmaceuticals began in 1995 as a small family business with a firm belief that our success could only be measured by the growth and success of our customers.

We are now **Australia's first choice for complementary medicines manufacturing** and
have won Seven prestigious Manufacturer of the
Year awards from the sectors industry association –
Complementary Medicines Australia.

As a contract manufacturer for Australia's biggest vitamin brands, our extensive services offer full supply chain management from product concept to market launch. This includes but is not limited to Product Development, Regulatory and Compliance Support, Research and Development, Quality Management, Stability Programs, Manufacturing and Packaging Solutions.

CONTAINS

French maritime pine tree (Pinus pinaster) extract

TARGETS

- Cardiovascular Health
- Skin Health
- Urinary Health
- Muscle Health
- Post-menopause
- Antioxidant
- Vein Health

APPLICATIONS

- Tablets
- Capsules
- Powders
- Oil-based Liquids





ADDRESS

21 Reaghs Farm Rd, Minto NSW, Australia 2566

TEL+61 2 8796 1400

MAIL info@Lipa.com.au

WEB www.Lipa.com.au

The above information is confidential, proprietary, and/or the intellectual property of Lipa Pharmaceuticals Australia Pty Ld. It may be neither transferred nor copied to any third party without the prior written consent of Lipa Pharmaceuticals or its subsidiary or affiliated companies. Disclaimer: Lipa Pharmaceuticals Australia Pty Ltd, nor its employees, accepts liability for any information provided that is not supported by The Therapeutic Goods Administration or other relevant regulatory agencies. While reasonable care has been taken to ensure that the information provided herein is accurate, this document is not an authoritative statement under the rules and regulations of the Therapeutic Goods Administration or other regulatory bodies.